MD Anderson and Virogin Biotech announce strategic collaboration to accelerate oncolytic virus research and development for treating advanced cancers
September 08, 2022
September 08, 2022
HOUSTON, Texas, Sept. 8 (TNSres) -- The University of Texas's MD Anderson Cancer Center issued the following news release on Sept. 7, 2022:
The University of Texas MD Anderson Cancer Center and Virogin Biotech today announced a strategic collaboration to accelerate the development of investigational treatments, including oncolytic viruses and immunotherapies, for patients with advanced cancers.
The agreement brings together MD Anderson's clinical trials expert . . .
The University of Texas MD Anderson Cancer Center and Virogin Biotech today announced a strategic collaboration to accelerate the development of investigational treatments, including oncolytic viruses and immunotherapies, for patients with advanced cancers.
The agreement brings together MD Anderson's clinical trials expert . . .